Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AMRX vs $LGND | Chartloom

Compare

$AMRX vs $LGND

Amneal Pharmaceuticals Inc · Ligand Pharmaceuticals Inc

AMRX

Amneal Pharmaceuticals Inc

LGND

Ligand Pharmaceuticals Inc

Compare $AMRX vs $LGND

Comparing Amneal Pharmaceuticals Inc and Ligand Pharmaceuticals Inc

AMRXAmneal Pharmaceuticals Inc

LGNDLigand Pharmaceuticals Inc

AMRXAmneal Pharmaceuticals Inc

Market cap

$6.25B

P/E (TTM)

40.80x

Forward P/E (NTM)

19.08x

Forward P/S (NTM)

1.89x

Rev growth (TTM)

9.3%

YTD performance

54.6%

52W performance

96.3%

FCF yield

-0.2%

LGNDLigand Pharmaceuticals Inc

Market cap

$6.08B

P/E (TTM)

33.61x

Forward P/E (NTM)

28.81x

Forward P/S (NTM)

17.73x

Rev growth (TTM)

54.9%

YTD performance

59.7%

52W performance

70.8%

FCF yield

2.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AMRX

LGND

Detailed metrics comparison

AMRX

Amneal Pharmaceuticals Inc

LGND

Ligand Pharmaceuticals Inc

Market Cap

AMRX$6.25B

LGND$6.08B

Enterprise Value

AMRX$8.85B

LGND$6.20B

Price

AMRX$19.57

LGND$303.53

P/E Ratio

AMRX40.80x

LGND33.61x

P/S Ratio

AMRX2.00x

LGND20.94x

EV/Sales

AMRX2.84x

LGND21.35x

EV/EBITDA

AMRX13.14x

LGND42.81x

P/B Ratio

AMRX192.54x

LGND6.22x

P/FCF Ratio

AMRXN/A

LGND45.31x

EV/FCF

AMRX-719.11x

LGND46.20x

PEG Ratio

AMRX1.98x

LGND1.33x

Forward P/E (NTM)

AMRX19.08x

LGND28.81x

Forward P/S (NTM)

AMRX1.89x

LGND17.73x

Revenue (TTM)

AMRX$3.12B

LGND$291M

Revenue Growth (YoY)

AMRX9.3%

LGND54.9%

Forward Rev Growth

AMRX9.0%

LGND31.3%

Gross Margin (TTM)

AMRX39.3%

LGND95.4%

Operating Margin (TTM)

AMRX14.6%

LGND32.6%

EBITDA Margin (TTM)

AMRX21.6%

LGND45.8%

Net Margin (TTM)

AMRX5.0%

LGND67.9%

FCF Margin (TTM)

AMRX-0.4%

LGND46.2%

Net Income (TTM)

AMRX$157M

LGND$197M

FCF (TTM)

AMRX$-12M

LGND$134M

EPS (TTM)

AMRX$0.48

LGND$9.03

ROE (TTM)

AMRX174.6%

LGND20.1%

ROA (TTM)

AMRX4.3%

LGND11.7%

ROIC (TTM)

AMRX2.1%

LGND12.3%

Cash

AMRX$128M

LGND$1.01B

Debt

AMRX$2.73B

LGND$1.13B

Net Cash/Debt

AMRX$-2.60B

LGND$-120M

Current Ratio (TTM)

AMRX2.20x

LGND31.18x

Quick Ratio (TTM)

AMRX1.38x

LGND30.96x

Debt/Equity (TTM)

AMRX82.62x

LGND1.16x

Debt/Assets (TTM)

AMRX0.0%

LGND0.0%

Interest Coverage (TTM)

AMRXN/A

LGNDN/A

Net Debt/EBITDA (TTM)

AMRX0.00x

LGND0.00x

Beta

AMRX1.22

LGND1.23

52W Performance

AMRX96.3%

LGND70.8%

YTD Performance

AMRX54.6%

LGND59.7%

% from 52W High

AMRX-7.6%

LGND-7.1%

% from 52W Low

AMRX104.7%

LGND72.6%

Asset Turnover (TTM)

AMRX0.85x

LGND0.17x

FCF Yield (TTM)

AMRX-0.2%

LGND2.2%

Earnings Yield (TTM)

AMRX2.5%

LGND3.2%

Dividend Yield (TTM)

AMRXN/A

LGNDN/A

Rule of 40

AMRX8.9

LGND101.1

EV/GP/RG

AMRX1.16

LGND1.14

Ticker research

View AMRX research View LGND research

Metric	AMRX Amneal Pharmaceuticals Inc	LGND Ligand Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.25B	$6.08B
Enterprise Value	$8.85B	$6.20B
Price	$19.57	$303.53
P/E Ratio	40.80x	33.61x
P/S Ratio	2.00x	20.94x
EV/Sales	2.84x	21.35x
EV/EBITDA	13.14x	42.81x
P/B Ratio	192.54x	6.22x
P/FCF Ratio	N/A	45.31x
EV/FCF	-719.11x	46.20x
PEG Ratio	1.98x	1.33x
Forward P/E (NTM)	19.08x	28.81x
Forward P/S (NTM)	1.89x	17.73x
Revenue & Growth
Revenue (TTM)	$3.12B	$291M
Revenue Growth (YoY)	9.3%	54.9%
Forward Rev Growth	9.0%	31.3%
Profitability
Gross Margin (TTM)	39.3%	95.4%
Operating Margin (TTM)	14.6%	32.6%
EBITDA Margin (TTM)	21.6%	45.8%
Net Margin (TTM)	5.0%	67.9%
FCF Margin (TTM)	-0.4%	46.2%
Net Income (TTM)	$157M	$197M
FCF (TTM)	$-12M	$134M
EPS (TTM)	$0.48	$9.03
ROE (TTM)	174.6%	20.1%
ROA (TTM)	4.3%	11.7%
ROIC (TTM)	2.1%	12.3%
Financial Health
Cash	$128M	$1.01B
Debt	$2.73B	$1.13B
Net Cash/Debt	$-2.60B	$-120M
Current Ratio (TTM)	2.20x	31.18x
Quick Ratio (TTM)	1.38x	30.96x
Debt/Equity (TTM)	82.62x	1.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.22	1.23
52W Performance	96.3%	70.8%
YTD Performance	54.6%	59.7%
% from 52W High	-7.6%	-7.1%
% from 52W Low	104.7%	72.6%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.17x
FCF Yield (TTM)	-0.2%	2.2%
Earnings Yield (TTM)	2.5%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.9	101.1
EV/GP/RG	1.16	1.14
Ticker research	View AMRX research	View LGND research

Valuation

P/E Ratio

LGND

33.61x

AMRX

40.80x

P/S Ratio

AMRX

2.00x

LGND

20.94x

EV/FCF

AMRX

-719.11x

LGND

46.20x

Growth & revenue

Revenue Growth TTM

LGND

54.9%

AMRX

9.3%

Forward Revenue Growth

LGND

31.3%

AMRX

9.0%

Profitability & performance

Gross Margin

LGND

95.4%

AMRX

39.3%

ROE

AMRX

174.6%

LGND

20.1%

FCF Yield %

LGND

2.2%

AMRX

-0.2%

52-Week Performance

AMRX

96.3%

LGND

70.8%

Detailed metrics comparison

AMRX

Amneal Pharmaceuticals Inc

LGND

Ligand Pharmaceuticals Inc

Market Cap

AMRX$6.25B

LGND$6.08B

Enterprise Value

AMRX$8.85B

LGND$6.20B

Price

AMRX$19.57

LGND$303.53

P/E Ratio

AMRX40.80x

LGND33.61x

P/S Ratio

AMRX2.00x

LGND20.94x

EV/Sales

AMRX2.84x

LGND21.35x

EV/EBITDA

AMRX13.14x

LGND42.81x

P/B Ratio

AMRX192.54x

LGND6.22x

P/FCF Ratio

AMRXN/A

LGND45.31x

EV/FCF

AMRX-719.11x

LGND46.20x

PEG Ratio

AMRX1.98x

LGND1.33x

Forward P/E (NTM)

AMRX19.08x

LGND28.81x

Forward P/S (NTM)

AMRX1.89x

LGND17.73x

Revenue (TTM)

AMRX$3.12B

LGND$291M

Revenue Growth (YoY)

AMRX9.3%

LGND54.9%

Forward Rev Growth

AMRX9.0%

LGND31.3%

Gross Margin (TTM)

AMRX39.3%

LGND95.4%

Operating Margin (TTM)

AMRX14.6%

LGND32.6%

EBITDA Margin (TTM)

AMRX21.6%

LGND45.8%

Net Margin (TTM)

AMRX5.0%

LGND67.9%

FCF Margin (TTM)

AMRX-0.4%

LGND46.2%

Net Income (TTM)

AMRX$157M

LGND$197M

FCF (TTM)

AMRX$-12M

LGND$134M

EPS (TTM)

AMRX$0.48

LGND$9.03

ROE (TTM)

AMRX174.6%

LGND20.1%

ROA (TTM)

AMRX4.3%

LGND11.7%

ROIC (TTM)

AMRX2.1%

LGND12.3%

Cash

AMRX$128M

LGND$1.01B

Debt

AMRX$2.73B

LGND$1.13B

Net Cash/Debt

AMRX$-2.60B

LGND$-120M

Current Ratio (TTM)

AMRX2.20x

LGND31.18x

Quick Ratio (TTM)

AMRX1.38x

LGND30.96x

Debt/Equity (TTM)

AMRX82.62x

LGND1.16x

Debt/Assets (TTM)

AMRX0.0%

LGND0.0%

Interest Coverage (TTM)

AMRXN/A

LGNDN/A

Net Debt/EBITDA (TTM)

AMRX0.00x

LGND0.00x

Beta

AMRX1.22

LGND1.23

52W Performance

AMRX96.3%

LGND70.8%

YTD Performance

AMRX54.6%

LGND59.7%

% from 52W High

AMRX-7.6%

LGND-7.1%

% from 52W Low

AMRX104.7%

LGND72.6%

Asset Turnover (TTM)

AMRX0.85x

LGND0.17x

FCF Yield (TTM)

AMRX-0.2%

LGND2.2%

Earnings Yield (TTM)

AMRX2.5%

LGND3.2%

Dividend Yield (TTM)

AMRXN/A

LGNDN/A

Rule of 40

AMRX8.9

LGND101.1

EV/GP/RG

AMRX1.16

LGND1.14

Ticker research

View AMRX research View LGND research

Metric	AMRX Amneal Pharmaceuticals Inc	LGND Ligand Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.25B	$6.08B
Enterprise Value	$8.85B	$6.20B
Price	$19.57	$303.53
P/E Ratio	40.80x	33.61x
P/S Ratio	2.00x	20.94x
EV/Sales	2.84x	21.35x
EV/EBITDA	13.14x	42.81x
P/B Ratio	192.54x	6.22x
P/FCF Ratio	N/A	45.31x
EV/FCF	-719.11x	46.20x
PEG Ratio	1.98x	1.33x
Forward P/E (NTM)	19.08x	28.81x
Forward P/S (NTM)	1.89x	17.73x
Revenue & Growth
Revenue (TTM)	$3.12B	$291M
Revenue Growth (YoY)	9.3%	54.9%
Forward Rev Growth	9.0%	31.3%
Profitability
Gross Margin (TTM)	39.3%	95.4%
Operating Margin (TTM)	14.6%	32.6%
EBITDA Margin (TTM)	21.6%	45.8%
Net Margin (TTM)	5.0%	67.9%
FCF Margin (TTM)	-0.4%	46.2%
Net Income (TTM)	$157M	$197M
FCF (TTM)	$-12M	$134M
EPS (TTM)	$0.48	$9.03
ROE (TTM)	174.6%	20.1%
ROA (TTM)	4.3%	11.7%
ROIC (TTM)	2.1%	12.3%
Financial Health
Cash	$128M	$1.01B
Debt	$2.73B	$1.13B
Net Cash/Debt	$-2.60B	$-120M
Current Ratio (TTM)	2.20x	31.18x
Quick Ratio (TTM)	1.38x	30.96x
Debt/Equity (TTM)	82.62x	1.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.22	1.23
52W Performance	96.3%	70.8%
YTD Performance	54.6%	59.7%
% from 52W High	-7.6%	-7.1%
% from 52W Low	104.7%	72.6%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.17x
FCF Yield (TTM)	-0.2%	2.2%
Earnings Yield (TTM)	2.5%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.9	101.1
EV/GP/RG	1.16	1.14
Ticker research	View AMRX research	View LGND research